Back to Search
Start Over
Outcomes of relapsed mantle cell lymphoma patients after discontinuing acalabrutinib.
- Source :
-
American journal of hematology [Am J Hematol] 2021 May 01; Vol. 96 (5), pp. E137-E140. Date of Electronic Publication: 2021 Feb 11. - Publication Year :
- 2021
- Subjects :
- Antineoplastic Agents adverse effects
Benzamides adverse effects
Combined Modality Therapy
Disease Progression
Drug Substitution
Follow-Up Studies
Humans
Immunotherapy, Adoptive
Kaplan-Meier Estimate
Lymphoma, Mantle-Cell genetics
Lymphoma, Mantle-Cell therapy
Mutation
Protein Kinase Inhibitors adverse effects
Pyrazines adverse effects
Recurrence
Salvage Therapy
Sample Size
Treatment Outcome
Exome Sequencing
Withholding Treatment
Antineoplastic Agents therapeutic use
Benzamides therapeutic use
Lymphoma, Mantle-Cell drug therapy
Protein Kinase Inhibitors therapeutic use
Pyrazines therapeutic use
Subjects
Details
- Language :
- English
- ISSN :
- 1096-8652
- Volume :
- 96
- Issue :
- 5
- Database :
- MEDLINE
- Journal :
- American journal of hematology
- Publication Type :
- Editorial & Opinion
- Accession number :
- 33491779
- Full Text :
- https://doi.org/10.1002/ajh.26109